Breast cancer

Updated 08 November 2017

Tamoxifen cuts second cancer risk

Taking tamoxifen is tied to a sharply reduced risk of a second breast cancer among women who carry certain genes, new research shows.

Taking tamoxifen is tied to a sharply reduced risk of a second breast cancer among women who carry the BRCA1 or BRCA2 "breast cancer genes," new research shows.

Women with mutations of those genes are much more likely to develop breast and ovarian cancer than other women. Some like Angelina Jolie will opt to have their breasts removed pre-emptively, which reduces breast cancer risk by more than 95%.

Other women may choose to have their ovaries removed, which cuts breast cancer risk in half. The new findings suggest taking tamoxifen may be another breast cancer preventing option for those women, whether or not they have already had cancer once, researchers said.

"In light of our finding, women with a BRCA1 or BRCA2 mutation should review their cancer risk management options with their specialist clinician," Dr Kelly-Anne Phillips of the Peter MacCallum Cancer Centre in Victoria, Australia, the study's lead author, told Reuters Health. Many breast cancer patients have tumours that grow and spread when exposed to oestrogen.

 Women with these hormone responsive cancers are typically prescribed tamoxifen, which blocks oestrogen and reduces their risk of cancer recurrence by 40%. But women with breast cancer who have BRCA1 or BRCA2 gene mutations are not typically offered tamoxifen treatment.

Results analysis

"There were very few BRCA1 and BRCA2 mutation carriers in previous studies of tamoxifen for breast cancer prevention, so there has been inadequate information about whether tamoxifen is useful in that specific group of women," Phillips said in an email.

To investigate whether the drug might help these high-risk women, Phillips and her colleagues analysed the results of three studies including a total of 1 583 BRCA1 mutation carriers and 881 BRCA2 carriers who had developed cancer in one breast.

24% of the BRCA1 carriers and 52% of the BRCA2 carriers began taking tamoxifen after being diagnosed. During an average of eight years of follow-up, 520 women – 24% of the BRCA1 carriers and 17% of the BRCA2 carriers – developed cancer in the opposite breast.

 Women with the BRCA1 mutation were 62% less likely to develop a second cancer if they took tamoxifen, while BRCA2 carriers had a 67% lower risk with the drug.

Tamoxifen was tied to fewer second cancers whether or not women's original tumours had been oestrogen-responsive, according to findings published in the Journal of Clinical Oncology. "Our study suggests tamoxifen should now be considered for all BRCA1 and BRCA2 mutation carriers who have had breast cancer... if they have chosen not to have all their breast tissue removed," Phillips said.

Preventing first cancers

Women who carry the BRCA1 or BRCA2 mutation who have not developed breast cancer may want to consider taking tamoxifen as well, Phillips added. "For BRCA1 and BRCA2 mutation carriers, tamoxifen should be considered while they are young and pre-menopausal because these women are at risk of breast cancer at an early age," she said.

The American Society of Clinical Oncology says a 5-year course of tamoxifen should be discussed for women age 35 and older at increased risk of breast cancer."The most common side-effect is menopausal symptoms, such as hot flushes," Phillips said.

"Most women find these tolerable but many women like to make a plan to try tamoxifen for a month or two to see how it feels, before finalising a plan to use it for the recommended 5 years. "Generic tamoxifen can be bought for about R1 000 per month or less. Dr Steven Narod, a professor at the Women's College Research Institute at the University of Toronto, said he frequently prescribes tamoxifen to prevent breast cancer among women with BRCA1 or BRCA2 mutations who do not choose to have their breasts removed.

"I've been recommending tamoxifen in that sense for many years to prevent breast cancer," Narod, who did not take part in the new study, told Reuters Health. "Very few doctors do. I think that this paper gives some pretty good support for the position that we should be using tamoxifen to prevent breast cancer in BRCA1 and BRCA2 carriers.

"Tamoxifen makes less sense as a treatment for BRCA1 or BRCA2 carriers who have already had breast cancer, he added. For these women, Narod said, the main treatment options are removal of the breasts or ovaries and chemotherapy."Tamoxifen has a role to play, but only I'd say a secondary one," he said.


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules